Can J&J and Pharmacyclics Help Fix Health Care?

The personal and emotional elements of health care have long separated the industry from many of the forces that drive other forms of business. Unfortunately, those same elements have contributed to the unsustainable path that our nation's health-care spending is on. However, in the following video Brenton Flynn outlines one technology that, if used appropriately, could help patients immensely, while also making our health-care system more cost-efficient.

Is bigger really better?
Involved in everything from baby powder to biotech, Johnson & Johnson's critics are convinced that the company is spread way too thin. If you want to know if J&J is nothing but a bloated corporate whale -- or a well-diversified giant that's perfect for your portfolio -- check out the Fool's new premium report outlining the Johnson & Johnson story in terms that any investor can understand. Claim your copy, and a year of free analyst updates, by clicking here now.

The article Can J&J and Pharmacyclics Help Fix Health Care? originally appeared on Fool.com.

Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends Genomic Health and Johnson & Johnson. The Motley Fool owns shares of Genomic Health and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.